Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Inc. Class A

Analysts have been eager to weigh in on the NA sector with new ratings on BioAge Labs, Inc. (BIOA) and Fiserv (FISV). BioAge Labs, Inc. (BIOA) In a...

Analysts’ Opinions Are Mixed on These NA Stocks: BioAge Labs, Inc. (BIOA) and Fiserv (FISV)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceut...

Analysts’ Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceutical (RARE)

In a report released today, Brandon Couillard from Wells Fargo maintained a Hold rating on Bio-Rad Laboratories, with a price target of $330.00. Ac...

Wells Fargo Remains a Hold on Bio-Rad Laboratories (BIO)

Citi analyst Daniel Grosslight maintained a Hold rating on Bio-Rad Laboratories today and set a price target of $330.00. According to TipRanks, Gro...

Citi Reaffirms Their Hold Rating on Bio-Rad Laboratories (BIO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO...

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO)

Analysts see a few thematic ETFs that stand out this August for investors seeking long‑run growth in digital assets and healthcare. These include t...

3 Best ETFs With 50%+ Upside to Buy in August 2026, According to Analysts

The latest update is out from Swedish Orphan Biovitrum AB ( ($SE:SOBI) ). Swedish Orphan Biovitrum AB has announced that Chief Executive Officer Gu...

Sobi CEO Guido Oelkers to Step Down in Early 2027

Analysts have been eager to weigh in on the NA sector with new ratings on BioAge Labs, Inc. (BIOA) and adidas AG (GB:0OLD). BioAge Labs, Inc. (BIOA...

Analysts Have Conflicting Sentiments on These NA Companies: BioAge Labs, Inc. (BIOA) and adidas AG (GB:0OLD)

In a report released today, Adam Walsh from Roth MKM maintained a Buy rating on BioAge Labs, Inc., with a price target of $25.00. According to TipR...

Roth MKM Reaffirms Their Buy Rating on BioAge Labs, Inc. (BIOA)

In a report released today, from Wedbush maintained a Buy rating on Crescent Biopharma, with a price target of $27.00. In addition to Wedbush, Cres...

Crescent Biopharma (CBIO) Gets a Buy from Wedbush

In a report released today, Joseph Stringer from Needham maintained a Buy rating on BioAge Labs, Inc., with a price target of $35.00. Stringer cove...

Needham Keeps Their Buy Rating on BioAge Labs, Inc. (BIOA)

Biome Australia Ltd ( ($AU:BIO) ) has provided an announcement. Biome Australia has cemented its position in the microbiome health sector, reportin...

Biome Australia posts record sales as Biome Daily tops probiotic market

Insiders have been trading these 5 stocks: (($TRV)), (($TDG)), (($CYTK)), (($GLBE)) and (($CBIO)). Here is a breakdown of their recent trades and t...

Travelers, TransDigm, Cytokinetics, Global-e, Crescent Shock Moves

The latest announcement is out from BB Biotech ( ($CH:BION) ). BB Biotech AG, a specialist biotech investment company listed in Switzerland and Ger...

BB Biotech posts strong interim profit and shifts to yield-based dividend policy

An update from BB Biotech ( ($CH:BION) ) is now available. BB Biotech reported a strong second quarter of 2026, with its net asset value delivering...

BB Biotech posts strong Q2, boosts AI-driven investing and revises dividend policy

WSW, NY, July 23rd, 2026, FinanceWire Nuvectis Pharma (NASDAQ:NVCT) announced this morning that ciprocopan (NXP100) has been approved by China’s Na...

Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

Biosynex SA ( ($FR:ALBIO) ) just unveiled an announcement. Biosynex reported first-half 2026 revenue of €44.1M, a 13% year-on-year decline, as its ...

Biosynex H1 Revenue Falls as Restructuring and Debt Safeguard Progress

Ibio ( ($IBIO) ) has shared an update. iBio, Inc. has scheduled its 2026 Annual Meeting of Stockholders for October 14, 2026, with a record date of...

iBio Updates Governance Deadlines for 2026 Annual Meeting

Berenberg Bank analyst Harry Gillis maintained a Buy rating on Swedish Orphan Biovitrum AB yesterday and set a price target of SEK575.00. The compa...

Berenberg Bank Remains a Buy on Swedish Orphan Biovitrum AB (0MTD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on RxSight (RXST), Kazia Therapeutics (KZIA) and Cres...

Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO)

An update from Swedish Orphan Biovitrum AB ( ($SE:SOBI) ) is now available. Sobi reported strong second-quarter 2026 results, with total revenue ri...

Sobi lifts 2026 outlook as Q2 revenue surges and gout pipeline advances

Swedish Orphan Biovitrum AB ( ($SE:SOBI) ) has shared an update. Sobi’s board has decided to repurchase all issued class C shares to secure the com...

Sobi Moves to Repurchase Class C Shares to Support Employee Incentive Programme

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BridgeBio Pharma (BBIO), Healthequity (HQY) and Alny...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIO	$352.47	+2.93%	266.85K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIO	$352.47	+2.9%	266.85K
3
4
5
6

BIO

BIO

Get Bio-Rad Laboratories Inc. Class A Data in Excel

Get Bio-Rad Laboratories Inc. Class A Data in Excel